Skip to main content

Research Repository

Advanced Search

Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study

Ingram, John; Thomas, Kim; Cannings, Rebecca; Evans, Judith; Gibbons, Angela; Howes, Rachel; Riaz, Muhammad; Stanton, Helen; Thomas-Jones, Emma; Collier, Fiona; Harris, Ceri; Rodrigues, Jeremy; Bates, Janine; Howells, Laura; Leighton, Paul

Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study Thumbnail


Authors

John Ingram

Rebecca Cannings

Judith Evans

Angela Gibbons

Rachel Howes

Muhammad Riaz

Helen Stanton

Emma Thomas-Jones

Fiona Collier

Ceri Harris

Jeremy Rodrigues

Janine Bates

LAURA HOWELLS LAURA.HOWELLS1@NOTTINGHAM.AC.UK
Senior Research Fellow

PAUL LEIGHTON PAUL.LEIGHTON@NOTTINGHAM.AC.UK
Associate Professor of Applied Health Services Research



Abstract

Background

Hidradenitis suppurativa (HS) is a chronic, painful disease affecting flexures and other skin regions, producing nodules, abscesses and skin tunnels. Laser treatment targeting hair follicles and deroofing of skin tunnels are standard HS interventions in some countries but rarely offered in the UK.

Objectives

To describe current UK HS management pathways and influencing factors to inform the design of future randomised controlled trials (RCTs).

Methods

THESEUS was a non-randomised 12-month prospective cohort study set in 10 UK hospitals offering five interventions: oral doxycycline 200mg daily; oral clindamycin and rifampicin both 300mg twice daily for 10 weeks, extended for longer in some cases; laser treatment targeting hair follicles; deroofing, and conventional surgery. Primary outcome was the combination of clinician-assessed eligibility and participant hypothetical willingness to receive each intervention. Secondary outcomes: proportion of participants selecting each intervention as their final treatment option; proportion who switch treatments; treatment fidelity, and attrition rates.

THESEUS was prospectively registered on ISRCTN Registry: ISRCTN69985145.

Results

The recruitment target of 150 participants was met after 18 months, in July 2021, with two pauses due to the Covid-19 pandemic. Baseline demographics reflected the HS secondary care population: average age 36 years, 81% female, 20% non-white, 64% current or ex-smokers, 86% BMI≥25, 68% moderate disease, 19% severe, and 13% mild disease. Laser was the intervention with the highest proportion (69%) of participants eligible and willing to receive treatment, then deroofing (58%), conventional surgery (54%), clindamycin and rifampicin (44%), and doxycycline (37%). Laser was ranked first choice by the greatest proportion of participants (41%). Attrition rates were 11% and 17% after three and six months respectively. Concordance with doxycycline was 52% after three months due to lack of efficacy, participant choice and adverse effects. Delays with procedural interventions were common, with only 43% and 26% of participants starting laser and deroofing respectively after three months. Uptake of conventional surgery was too small to characterise the intervention. Switching treatment was uncommon and there were no serious adverse events.

Conclusions

THESEUS established laser treatment and deroofing for HS in the UK and demonstrated their popularity with patients and clinicians for future RCTs.

Citation

Ingram, J., Thomas, K., Cannings, R., Evans, J., Gibbons, A., Howes, R., …Leighton, P. (2024). Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study. British Journal of Dermatology, 190(3), 382-391. https://doi.org/10.1093/bjd/ljad388

Journal Article Type Article
Acceptance Date Oct 10, 2023
Online Publication Date Oct 12, 2023
Publication Date 2024-03
Deposit Date Dec 12, 2023
Publicly Available Date Oct 13, 2024
Journal British Journal of Dermatology
Print ISSN 0007-0963
Electronic ISSN 1365-2133
Publisher Oxford University Press (OUP)
Peer Reviewed Peer Reviewed
Volume 190
Issue 3
Pages 382-391
DOI https://doi.org/10.1093/bjd/ljad388
Keywords Dermatology
Public URL https://nottingham-repository.worktribe.com/output/25956713
Publisher URL https://academic.oup.com/bjd/advance-article/doi/10.1093/bjd/ljad388/7308529
Additional Information © The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.